Akiyuki Uzawa1, Masahiro Mori, Saeko Masuda, Satoshi Kuwabara. 1. Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan. a-uzimp1204@graduate.chiba-u.jp
Abstract
OBJECTIVE: To evaluate the degree of blood-brain barrier disruption in patients with neuromyelitis optica (NMO) and to clarify whether the levels of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) in patients with NMO can be useful biomarkers for blood-brain barrier breakdown. DESIGN: Descriptive historical cohort. SETTING: Department of Neurology, Graduate School of Medicine, Chiba University. PATIENTS: The levels of sICAM-1 and sVCAM-1 in 25 patients with NMO, 21 patients with multiple sclerosis, and 20 patients with other noninflammatory neurologic disorders in the serum and cerebrospinal fluid (CSF) were measured using a multiplexed fluorescent magnetic bead-based immunoassay. MAIN OUTCOME MEASURES: Levels of the soluble adhesion molecules in serum and CSF and their associations with blood-brain barrier disruption. RESULTS: The CSF levels of sICAM-1 and sVCAM-1 increased in patients with NMO compared with patients with multiple sclerosis and other noninflammatory neurologic disorders (P < .001), and serum levels of sICAM-1 increased in patients with NMO compared with healthy control individuals (P = .003). The CSF sICAM-1 levels from patients with NMO were correlated with the albumin quotient (P = .02) and the presence of lesions detected via gadolinium-enhanced magnetic resonance imaging. CONCLUSIONS: Severe blood-brain barrier breakdown occurs in patients with NMO. Measuring adhesion molecules is useful to evaluate this barrier disruption.
OBJECTIVE: To evaluate the degree of blood-brain barrier disruption in patients with neuromyelitis optica (NMO) and to clarify whether the levels of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) in patients with NMO can be useful biomarkers for blood-brain barrier breakdown. DESIGN: Descriptive historical cohort. SETTING: Department of Neurology, Graduate School of Medicine, Chiba University. PATIENTS: The levels of sICAM-1 and sVCAM-1 in 25 patients with NMO, 21 patients with multiple sclerosis, and 20 patients with other noninflammatory neurologic disorders in the serum and cerebrospinal fluid (CSF) were measured using a multiplexed fluorescent magnetic bead-based immunoassay. MAIN OUTCOME MEASURES: Levels of the soluble adhesion molecules in serum and CSF and their associations with blood-brain barrier disruption. RESULTS: The CSF levels of sICAM-1 and sVCAM-1 increased in patients with NMO compared with patients with multiple sclerosis and other noninflammatory neurologic disorders (P < .001), and serum levels of sICAM-1 increased in patients with NMO compared with healthy control individuals (P = .003). The CSF sICAM-1 levels from patients with NMO were correlated with the albumin quotient (P = .02) and the presence of lesions detected via gadolinium-enhanced magnetic resonance imaging. CONCLUSIONS: Severe blood-brain barrier breakdown occurs in patients with NMO. Measuring adhesion molecules is useful to evaluate this barrier disruption.
Authors: J Sellner; W Koczi; A Harrer; K Oppermann; E Obregon-Castrillo; G Pilz; P Wipfler; S Afazel; E Haschke-Becher; E Trinka; J Kraus Journal: Clin Exp Immunol Date: 2013-09 Impact factor: 4.330
Authors: Katarina Nägga; Carina Wattmo; Yi Zhang; Lars-Olof Wahlund; Sebastian Palmqvist Journal: Alzheimers Res Ther Date: 2014-07-07 Impact factor: 6.982